Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin, Jelena Grahovac, Anamaria Brozović, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100715-100715
Open Access | Times Cited: 389

Showing 1-25 of 389 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1143
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Luciana Mosca, Andrea Ilari, Francesco Fazi, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100742-100742
Closed Access | Times Cited: 228
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 174
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients
Frederik L. Giesel, Clemens Kratochwil, Joel Schlittenhardt, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 13, pp. 4377-4385
Open Access | Times Cited: 162
Cancer drug resistance induced by EMT: novel therapeutic strategies
Javier De Las Rivas, Anamaria Brozović, Sivan Izraely, et al.
Archives of Toxicology (2021) Vol. 95, Iss. 7, pp. 2279-2297
Open Access | Times Cited: 147
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Tumor microenvironment signaling and therapeutics in cancer progression
Anshika Goenka, Fatima Khan, Bhupender Verma, et al.
Cancer Communications (2023) Vol. 43, Iss. 5, pp. 525-561
Open Access | Times Cited: 122
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment
Jiakang Jin, Jinti Lin, Ankai Xu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 120
Chronic inflammation, cancer development and immunotherapy
Yalei Wen, Ying‐Jie Zhu, Caishi Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 99
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance
Jingyi Fan, Kenneth K.W. To, Zhe‐Sheng Chen, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100905-100905
Open Access | Times Cited: 98
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 97
Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities
Zhao Huang, Zhe Zhang, Chengwei Zhou, et al.
MedComm (2022) Vol. 3, Iss. 2
Open Access | Times Cited: 94
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Kevin Dzobo, Dimakatso Alice Senthebane, Collet Dandara
Cancers (2023) Vol. 15, Iss. 2, pp. 376-376
Open Access | Times Cited: 94
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer
Xianlin Qu, Bing Liu, Longgang Wang, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100936-100936
Closed Access | Times Cited: 88
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Chenmala Karthika, R. Sureshkumar, Mehrukh Zehravi, et al.
Life (2022) Vol. 12, Iss. 6, pp. 897-897
Open Access | Times Cited: 82
Heterogeneity and plasticity of epithelial–mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms
Dandan Li, Lingyun Xia, Pan Huang, et al.
Cell Proliferation (2023) Vol. 56, Iss. 6
Open Access | Times Cited: 78
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100844-100844
Open Access | Times Cited: 71
Augmenting Immunotherapy via Bioinspired MOF‐Based ROS Homeostasis Disruptor with Nanozyme‐Cascade Reaction
Ruifang Wang, Maosong Qiu, Lei Zhang, et al.
Advanced Materials (2023) Vol. 35, Iss. 49
Closed Access | Times Cited: 63
Innovative strategies for photodynamic therapy against hypoxic tumor
Xiaotong Li, Lei Chen, Miaoting Huang, et al.
Asian Journal of Pharmaceutical Sciences (2023) Vol. 18, Iss. 1, pp. 100775-100775
Open Access | Times Cited: 56
Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer
Fei Li, Henghui Zhang, Yu‐An Huang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101059-101059
Closed Access | Times Cited: 56
The promising role of tumor-associated macrophages in the treatment of cancer
Hongbin Wang, Xueying Wang, Xin Zhang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101041-101041
Closed Access | Times Cited: 55
Deciphering the molecular landscape: integrating single-cell transcriptomics to unravel myofibroblast dynamics and therapeutic targets in clear cell renal cell carcinomas
Wenqian Zhou, Zhiheng Lin, Tan Wang
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 28
Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response
Nasim Ebrahimi, Mahdokht Sadat Manavi, Ferdos Faghihkhorasani, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 457-479
Closed Access | Times Cited: 27
The tumor microenvironment: a key player in multidrug resistance in cancer
Lingnan Meng, Ying Zheng, Hao Liu, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 41-58
Open Access | Times Cited: 18
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy
Xinyue Shao, Xiaoling Zhao, Binghao Wang, et al.
Theranostics (2025) Vol. 15, Iss. 5, pp. 1689-1714
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top